TY - JOUR
T1 - Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells
AU - Dodd, Megan
AU - Marquez-Curtis, Leah
AU - Janowska-Wieczorek, Anna
AU - Hortelano, Gonzalo
N1 - Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2014
Y1 - 2014
N2 - Background: Hemophilia B patients are subject to frequent and spontaneous bleeding caused by a deficiency of clotting factor IX (FIX). Mesenchymal stromal cells (MSCs) have been used in cellular therapies as a result of their immunomodulatory properties, the ability to home to sites of injury and their amenability to various ex vivo modifications, including lentiviral-mediated gene transfer. Methods: MSCs were isolated from human umbilical cord blood and differentiated into adipogenic, chondrogenic and osteogenic lineages. A lentiviral DNA vector containing the human FIX gene was generated using traditional restriction enzyme digest and ligation techniques to generate viable replication-incompetent lentiviral particles that were used to transduce MSCs. Quantitative measurement of FIX expression was conducted using an enzyme-linked immunosorbent assay. Results: The over-expression of FIX was sustained in vitro at levels>4 μg/106 cells/24 h and FIX coagulant activity was>2.5 mIU/106 cells/24 h for the 6-week duration of study. Lentiviral modification of cells with a multiplicity of infection of 10 did not adversely affect the potential of cord blood (CB) MSCs to differentiate to adipocytes, chondrocytes and osteoblastic cells, and the expression of functional FIX was sustained after differentiation and was similar to that in nondifferentiated cells. Conclusions: Modification of human CB MSCs with a lentiviral vector resulted in sustained high FIX expression in vitro after differentiation to adipogenic, chondrogenic and osteoblastic cells. These modified MSCs could have applications in cellular therapies for hemophilia B.
AB - Background: Hemophilia B patients are subject to frequent and spontaneous bleeding caused by a deficiency of clotting factor IX (FIX). Mesenchymal stromal cells (MSCs) have been used in cellular therapies as a result of their immunomodulatory properties, the ability to home to sites of injury and their amenability to various ex vivo modifications, including lentiviral-mediated gene transfer. Methods: MSCs were isolated from human umbilical cord blood and differentiated into adipogenic, chondrogenic and osteogenic lineages. A lentiviral DNA vector containing the human FIX gene was generated using traditional restriction enzyme digest and ligation techniques to generate viable replication-incompetent lentiviral particles that were used to transduce MSCs. Quantitative measurement of FIX expression was conducted using an enzyme-linked immunosorbent assay. Results: The over-expression of FIX was sustained in vitro at levels>4 μg/106 cells/24 h and FIX coagulant activity was>2.5 mIU/106 cells/24 h for the 6-week duration of study. Lentiviral modification of cells with a multiplicity of infection of 10 did not adversely affect the potential of cord blood (CB) MSCs to differentiate to adipocytes, chondrocytes and osteoblastic cells, and the expression of functional FIX was sustained after differentiation and was similar to that in nondifferentiated cells. Conclusions: Modification of human CB MSCs with a lentiviral vector resulted in sustained high FIX expression in vitro after differentiation to adipogenic, chondrogenic and osteoblastic cells. These modified MSCs could have applications in cellular therapies for hemophilia B.
KW - Coagulation factor IX
KW - Hemophilia B
KW - Lentiviral vector
KW - Mesenchymal stromal cells
UR - http://www.scopus.com/inward/record.url?scp=84904563461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904563461&partnerID=8YFLogxK
U2 - 10.1002/jgm.2769
DO - 10.1002/jgm.2769
M3 - Article
C2 - 24947827
AN - SCOPUS:84904563461
SN - 1099-498X
VL - 16
SP - 131
EP - 142
JO - Journal of Gene Medicine
JF - Journal of Gene Medicine
IS - 5-6
ER -